FI885331L - Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli. - Google Patents

Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli. Download PDF

Info

Publication number
FI885331L
FI885331L FI885331A FI885331A FI885331L FI 885331 L FI885331 L FI 885331L FI 885331 A FI885331 A FI 885331A FI 885331 A FI885331 A FI 885331A FI 885331 L FI885331 L FI 885331L
Authority
FI
Finland
Prior art keywords
thrombotisk
arteriell
emboli
thromb
occlusion
Prior art date
Application number
FI885331A
Other languages
English (en)
Other versions
FI885331A0 (fi
FI104790B (fi
Inventor
John H Griffin
Andras Gruber
Stephen R Hanson
Lawrence A Harker
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI885331(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI885331A0 publication Critical patent/FI885331A0/fi
Publication of FI885331L publication Critical patent/FI885331L/fi
Application granted granted Critical
Publication of FI104790B publication Critical patent/FI104790B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FI885331A 1987-11-17 1988-11-17 Menetelmä aktivoidun proteiini C:n valmistamiseksi FI104790B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12170287 1987-11-17
US07/121,702 US5084274A (en) 1987-11-17 1987-11-17 Inhibition of arterial thrombotic occlusion or thromboembolism

Publications (3)

Publication Number Publication Date
FI885331A0 FI885331A0 (fi) 1988-11-17
FI885331L true FI885331L (fi) 1989-05-18
FI104790B FI104790B (fi) 2000-04-14

Family

ID=22398288

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885331A FI104790B (fi) 1987-11-17 1988-11-17 Menetelmä aktivoidun proteiini C:n valmistamiseksi

Country Status (11)

Country Link
US (2) US5084274A (fi)
EP (1) EP0318201B1 (fi)
JP (1) JP2766986B2 (fi)
AT (1) ATE135234T1 (fi)
CA (1) CA1330036C (fi)
DE (1) DE3855096T2 (fi)
DK (1) DK175704B1 (fi)
ES (1) ES2086301T3 (fi)
FI (1) FI104790B (fi)
GR (1) GR3020036T3 (fi)
NO (1) NO301747B1 (fi)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
JP2739050B2 (ja) 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
WO1991009960A1 (en) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Hybrid protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
EP0580685B1 (de) * 1991-04-16 1996-01-03 Roche Diagnostics GmbH Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
AU703256B2 (en) * 1995-06-09 1999-03-25 Regents Of The University Of Michigan, The Bradykinin analogs as selective thrombin inhibitors
DE69833727T2 (de) * 1997-03-24 2006-08-31 Eli Lilly And Co., Indianapolis Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
DE69905489T2 (de) 1998-11-23 2003-09-11 Eli Lilly And Co., Indianapolis Protein c zur behandlung von sichelzellanämie und thalassämie
DE60144366D1 (de) * 2000-02-04 2011-05-19 Scripps Research Inst Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2004022153A2 (en) * 2002-09-05 2004-03-18 Genentech, Inc. Infusion catheter having an integrated doppler transducer
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7498305B2 (en) * 2003-07-08 2009-03-03 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1773371A4 (en) * 2004-07-23 2009-12-30 Univ Rochester ACTIVATED PROTEIN C INHIBITS SIDE EFFECTS OF PLASMINOGEN ACTIVATOR IN THE BRAIN
KR101315904B1 (ko) 2005-02-24 2013-10-08 디퓨젼 파마슈티컬즈 엘엘씨 트랜스 카로티노이드, 이들의 합성, 제제화 및 용도
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
WO2008073603A2 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
BRPI0810647A2 (pt) 2007-04-13 2014-11-04 Diffusion Pharmaceuticals Llc " uso de trans carotenóides bipolares como um pré-tratamento e no tratamento de doença vascular periférica ".
CN102458110A (zh) 2009-06-22 2012-05-16 扩散药品有限公司 扩散促进化合物及其单独或与溶栓药一起的应用
EP2575487B1 (en) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
CN106488773B (zh) 2014-04-16 2020-02-11 Zz生物技术有限责任公司 Apc类似物用于创伤愈合的用途
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
KR20230014850A (ko) 2016-03-24 2023-01-30 디퓨젼 파마슈티컬즈 엘엘씨 암을 치료하기 위한, 화학 요법 및 방사선 요법과의 양극성 트랜스 카로티노이드의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS6011427A (ja) * 1983-06-29 1985-01-21 Green Cross Corp:The 血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE93272T1 (de) * 1985-06-27 1993-09-15 Zymogenetics Inc Expression von protein c.
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis

Also Published As

Publication number Publication date
DK175704B1 (da) 2005-01-24
EP0318201A3 (en) 1990-02-07
ES2086301T3 (es) 1996-07-01
GR3020036T3 (en) 1996-08-31
NO301747B1 (no) 1997-12-08
EP0318201A2 (en) 1989-05-31
FI885331A0 (fi) 1988-11-17
DE3855096T2 (de) 1996-07-25
NO885109D0 (no) 1988-11-16
DK640088D0 (da) 1988-11-16
EP0318201B1 (en) 1996-03-13
NO885109L (no) 1989-05-18
JP2766986B2 (ja) 1998-06-18
FI104790B (fi) 2000-04-14
US5350578A (en) 1994-09-27
ATE135234T1 (de) 1996-03-15
DE3855096D1 (de) 1996-04-18
JPH01238536A (ja) 1989-09-22
DK640088A (da) 1989-05-18
US5084274A (en) 1992-01-28
CA1330036C (en) 1994-06-07

Similar Documents

Publication Publication Date Title
FI885331L (fi) Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli.
FI891348A0 (fi) Foerfarande foer tillverkning av papper eller kartong av aoterfoerbrukade, med entzymer behandlade fibrer.
FI883948L (fi) Spolvaetska foer foerstoerning av kroppsfraemmande avlagringar med intensiv, pulserande laserstraolning.
FI893930A0 (fi) Foerfarande foer framstaellning av vaxbeklaedda, foerdroejt frigjorda partiklar innehaollande tuggummi.
FI892174A0 (fi) Maskinens pressdel foer tillverkning av en fiberbana, speciellt pappersbana.
FI885380A7 (fi) Luftledningslaoda foer stabilisering av loepet av en varubana, saerskilt en pappersbana.
FI881152A0 (fi) Foerfarande foer framstaellning av tiazolderivat, med kolinergisk aktivitet.
FI906366L (fi) Nytt foerfarande foer framstaellning av 1-fenyl-imidazol-2,5-dionderivat.
FI871910A0 (fi) Foerfarande foer framstaellning av heparin med laog molekylvikt.
FI871909L (fi) Foerfarande foer framstaellning av heparin med laog molekylvikt.
FI880916A0 (fi) Anordning foer stabilisering av en materialbana, isynnerhet foer stabilisering av en pappersbana i torkpartiet i en pappersmaskin.
FI890113L (fi) Anvaendning av utvalda aendgruppsslutna fett-alkoholetoxylater foer skumbara, sprutbara rengoeringsmedel.
FI902774A0 (fi) N-imidazolyl- och n -imidazolylmetylderivat av substituerade, bicykliska foereningar.
FI880930A7 (fi) Anordning foer avskiljning av haorda foeremaol, saosom stenar fraon en stroem av traestammar.
FI891000L (fi) Slangformigt naeringsmedelsskal av cellulosahydrat, i synnerhet konstgjort korvskal.
FI884857A7 (fi) Anordning foer framstaellning av portabla, roerformiga paket av tryckalster.
FI885074L (fi) Foerfarande foer framstaellning av en vaetskeformig, elektrostatisk framkallare.
FI895923A0 (fi) Oralt, mindre missfaergande foerfarande foer foerhindrande av plack.
FI883415L (fi) Anordning foer styrning av en trefasig vaexelstroemsmotor, saerskilt en kortslutningsmotor.
FI883856L (fi) Kretsanordning foer generering av i,q-vaogformer.
FI880851A7 (fi) Anordning foer hopsaettning av skurna aemnen, saerskilt foer aostadkommande av foerpackningar.
FI894889A0 (fi) Gripanordning foer gripande av i stroem matade, vikta tryckprodukter.
FI885030A0 (fi) Anordning foer foerminskning eller malning av fiberaemnesmaterial, saerskilt en trumraffinoer.
FI884819A0 (fi) Foerfarande foer framstaellning av en elektriskt halvledande, lossnande plastblandning.
FI880073A0 (fi) Ramspaennanordning, saerskilt foer girfogning av ramar.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: SCRIPPS CLINIC AND RESEARCH FOUNDATION

MA Patent expired